Abstract Purpose: Human papillomavirus (HPV) DNA offers a convenient circulating tumor
DNA (ctDNA) marker for HPV-associated malignancies, but current methods, such as digital …

Background HPV-related cervical cancer (CC) is the fourth most frequent cancer in women
worldwide. Cell-free tumour DNA is a potent biomarker to detect treatment response …

Purpose: Use of circulating tumor DNA (ctDNA) for diagnosis is limited regarding the low
number of target molecules in early-stage tumors. Human papillomavirus (HPV)–associated …

Human papillomaviruses (HPVs) are associated with invasive malignancies, including
almost 100% of cervical cancers (CECs), and 35–70% of oropharyngeal cancers (OPCs) …

Purpose: Circulating cell-free (ccf) human papillomavirus (HPV) DNA may serve as a unique
tumor marker for HPV-associated malignancies, including cervical cancer. We developed a …

We aimed to determine whether pretherapeutic assessment of HPV circulating tumoral DNA
(HPV ctDNA) by droplet‐based digital PCR (ddPCR) could constitute a predictive and …

Human papillomavirus (HPV) circulating tumor DNA (HPV ctDNA) was proposed as a
biomarker for the detection and disease monitoring of HPV-related cancers. One hundred …

Objectives To develop a high-performance droplet digital PCR (ddPCR) assay capable of
enhancing the detection of human papillomavirus (HPV) circulating tumor DNA (ctDNA) in …

Human papillomavirus (HPV), most commonly HPV16, causes a growing subset of head
and neck squamous cell carcinomas (HNSCCs), including the overwhelming majority of …

Tumor cells release fragments of their DNA into the circulation, so called cell‐free tumor
DNA (ctDNA), allowing for analysis of tumor DNA in a simple blood test, that is, liquid biopsy …